Novo Nordisk announced on September 26, 2026, that it has signed an exclusive global license agreement with Swedish drug-delivery company Nanexa for its PharmaShell coating technology, a platform designed to extend how long injectable drugs, including peptides, remain active in the body.
What PharmaShell Does
PharmaShell is a coating process built on atomic layer deposition, a technique borrowed from semiconductor manufacturing that applies extremely thin, precisely controlled layers of material onto drug particles, one atomic layer at a time. In drug-delivery applications, that coating is used to slow and control the rate at which a drug is released into the body after injection. The general goal of this kind of technology is to let an injectable formulation act for longer between doses without changing the underlying drug molecule itself, by controlling how quickly the coated particles dissolve or break down once injected.
Deal Terms
Under the agreement, Nanexa is eligible to receive up to €1.165 billion (roughly $1.33 billion) in upfront and milestone payments, plus royalties on any resulting products. As with most biopharma licensing deals of this type, the large majority of that figure is contingent milestone payments tied to development and regulatory progress rather than guaranteed cash, so the deal's ultimate value to Nanexa will depend heavily on whether Novo Nordisk successfully advances a product using the technology through clinical development and to market.
Part of a Broader Industry Shift
The Nanexa license is one of several similar platform-licensing deals announced around the same period, including Eli Lilly's research collaboration with InnoCare Pharma covering cancer and autoimmune drug targets, AbbVie's AI-driven drug-discovery alliance with Iambic, and Novartis's radioligand therapy license with BoomRay. Industry observers have described this pattern as a shift away from the wave of outright company acquisitions that characterized earlier in 2026, toward large pharmaceutical companies instead licensing specific enabling technologies from smaller, more specialized firms. For Novo Nordisk in particular, the deal comes as the company faces intensifying competition from Eli Lilly across the obesity and GLP-1 drug market, and as it has separately laid out a broader diversification strategy targeting new blockbuster products beyond semaglutide.
What This Does and Doesn't Mean for Patients
If PharmaShell coating technology is eventually applied to a peptide drug and successfully cleared through clinical trials and regulatory review, the theoretical benefit for patients would be less frequent dosing, for example a monthly injection instead of a weekly one, for a given peptide therapy. That kind of extended-release approach is conceptually similar to what other companies have pursued through different chemistry, such as fatty acid conjugation or Fc-fusion, discussed in more detail in this site's guide to how peptide half-life gets extended. That said, this announcement is a technology license, not a product, and no specific drug candidate, clinical trial timeline, or regulatory filing has been disclosed alongside it. Platform-licensing deals like this one frequently take years to produce an approved product, and many never do.
The Bottom Line
This is a corporate and technology-licensing development, not a new treatment or a change to any existing GLP-1 medication's approved dosing. Patients currently using GLP-1 or other peptide injectables should continue following their prescribed dosing schedule and talk to their physician about any questions regarding their specific treatment, rather than anticipating changes based on early-stage platform deals like this one.